Abacus FCF Advisors LLC Invests $6.63 Million in Medpace Holdings, Inc. $MEDP

Key Points

• Abacus FCF Advisors acquired 12,529 Medpace shares worth approximately $6.63 million during the second quarter. Institutional investors collectively own 77.98% of the company.
• Medpace exceeded quarterly expectations, reporting $4.25 EPS versus the $3.98 consensus and $707.33 million in revenue, up 17.2% year over year. The company issued fiscal 2026 EPS guidance of $17.25–$17.95.
• Shares opened at $608.27, while analysts maintained a consensus “Hold” rating with a $584.18 target price. Meanwhile, insiders sold 67,195 shares worth nearly $38 million over the past three months.

Abacus FCF Advisors LLC acquired a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 12,529 shares of the company's stock, valued at approximately $6,635,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Johnson Financial Group Inc. purchased a new position in Medpace in the second quarter worth $27,000. Elyxium Wealth LLC acquired a new position in Medpace during the 4th quarter valued at about $30,000. Allied Private Wealth LLC acquired a new position in Medpace during the 2nd quarter valued at about $31,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in Medpace in the second quarter valued at about $34,000. Finally, Basecamp Wealth Advisors LLC raised its stake in Medpace by 187.5% in the first quarter. Basecamp Wealth Advisors LLC now owns 69 shares of the company's stock valued at $33,000 after buying an additional 45 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company's stock.

Medpace Price Performance

NASDAQ MEDP opened at $608.27 on Thursday. The company has a market capitalization of $16.98 billion, a PE ratio of 35.65, a P/E/G ratio of 2.63 and a beta of 1.15. The company has a fifty day moving average of $544.34 and a 200 day moving average of $491.59. Medpace Holdings, Inc. has a 1 year low of $373.00 and a 1 year high of $677.90.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping the consensus estimate of $3.98 by $0.27. The company had revenue of $707.33 million for the quarter, compared to the consensus estimate of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The firm's revenue for the quarter was up 17.2% compared to the same quarter last year. During the same period last year, the firm earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Research analysts expect that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Cornelius P. Mccarthy III sold 1,140 shares of the firm's stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $605.37, for a total transaction of $690,121.80. Following the sale, the director owned 12,275 shares in the company, valued at approximately $7,430,916.75. This trade represents a 8.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO August J. Troendle sold 17,610 shares of the firm's stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $605.11, for a total transaction of $10,655,987.10. Following the sale, the chief executive officer owned 615,802 shares in the company, valued at approximately $372,627,948.22. This represents a 2.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 67,195 shares of company stock valued at $37,989,998. Insiders own 20.50% of the company's stock.

Analyst Ratings Changes

MEDP has been the subject of several research analyst reports. Leerink Partners set a $620.00 price objective on shares of Medpace in a research report on Thursday, July 23rd. Weiss Ratings raised shares of Medpace from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Wednesday, August 12th. Royal Bank Of Canada upped their price target on shares of Medpace from $484.00 to $692.00 and gave the company an "outperform" rating in a research note on Friday, July 24th. BMO Capital Markets raised their price target on shares of Medpace from $400.00 to $600.00 and gave the stock a "market perform" rating in a report on Friday, July 24th. Finally, Mizuho lifted their price objective on shares of Medpace from $586.00 to $665.00 and gave the stock an "outperform" rating in a research note on Friday, July 24th. Three investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $584.18.

Medpace Profile

Medpace Holdings, Inc NASDAQ: MEDP is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source